Literature DB >> 20392211

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A paradigm for prenatal diagnosis and treatment.

Saroj Nimkarn1, Maria I New.   

Abstract

21-Hydroxylase deficiency is the most common cause of congenital adrenal hyperplasia (CAH), an inherited disorder of steroidogenesis. In its severe form, CAH causes genital ambiguity in females. Molecular genetic analysis of fetal DNA obtained by amniocentesis or chorionic villus sampling is used to diagnose steroid 21-OHD deficiency in utero. Large ongoing studies show that appropriate prenatal treatment of pregnant mothers with dexamethasone is effective and safe for both the fetus and the mother. It reduces ambiguous genitalia in the female affected fetus and thus avoids unnecessary genitoplasty in the newborn female.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392211     DOI: 10.1111/j.1749-6632.2009.05225.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Trophoblast Retrieval and Isolation From the Cervix for Noninvasive, First Trimester, Fetal Gender Determination in a Carrier of Congenital Adrenal Hyperplasia.

Authors:  Alan D Bolnick; Rani Fritz; Chandni Jain; Leena Kadam; Jay M Bolnick; Brian A Kilburn; Manvinder Singh; Michael P Diamond; Sascha Drewlo; D Randall Armant
Journal:  Reprod Sci       Date:  2016-02-25       Impact factor: 3.060

2.  Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma.

Authors:  Maria I New; Yu K Tong; Tony Yuen; Peiyong Jiang; Christian Pina; K C Allen Chan; Ahmed Khattab; Gary J W Liao; Mabel Yau; Se-Min Kim; Rossa W K Chiu; Li Sun; Mone Zaidi; Y M Dennis Lo
Journal:  J Clin Endocrinol Metab       Date:  2014-02-28       Impact factor: 5.958

3.  Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model.

Authors:  Hazem Ali; Irina Kalashnikova; Mark Andrew White; Michael Sherman; Erik Rytting
Journal:  Int J Pharm       Date:  2013-07-12       Impact factor: 5.875

Review 4.  The DABBEC phenotyping system: towards a mechanistic understanding of CP/CPPS.

Authors:  Stephen A Allsop; Derek J Erstad; Karolina Brook; Salman F Bhai; Jeffrey M Cohen; Jordan D Dimitrakoff
Journal:  Nat Rev Urol       Date:  2011-01-18       Impact factor: 14.432

5.  Experts' Opinion on the Prenatal Therapy of Congenital Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency - Guideline of DGKED in cooperation with DGGG (S1-Level, AWMF Registry No. 174/013, July 2015).

Authors:  H G Dörr; G Binder; N Reisch; U Gembruch; P G Oppelt; P Wieacker; J Kratzsch
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-12       Impact factor: 2.915

Review 6.  Gestational Hyperandrogenism in Developmental Programming.

Authors:  Christopher Hakim; Vasantha Padmanabhan; Arpita K Vyas
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

Review 7.  Congenital adrenal hyperplasia in pregnancy: approach depends on who is the 'patient'.

Authors:  Erin Keely; Janine Malcolm
Journal:  Obstet Med       Date:  2012-09-24

8.  Genetic risk.

Authors:  Leo P Ten Kate
Journal:  J Community Genet       Date:  2012-08-15

Review 9.  Treatment and health outcomes in adults with congenital adrenal hyperplasia.

Authors:  Thang S Han; Brian R Walker; Wiebke Arlt; Richard J Ross
Journal:  Nat Rev Endocrinol       Date:  2013-12-17       Impact factor: 43.330

10.  Prenatal Dexamethasone for Congenital Adrenal Hyperplasia: An Ethics Canary in the Modern Medical Mine.

Authors:  Alice Dreger; Ellen K Feder; Anne Tamar-Mattis
Journal:  J Bioeth Inq       Date:  2012-07-31       Impact factor: 1.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.